Reme.D
Location
Egypt, Kenya, Sudan
Sector
Public health
Type of investment
Risk capital
Project stage
Test and transition
Length of investment
2026+
Website
Investment overview
Reme.D is an Egyptian biotech company designing and manufacturing affordable, locally made medical test kits for low-resource health settings. Reme.D enables healthcare providers to diagnose infectious and non-communicable diseases faster and more reliably than before.
The development challenge
Reliable healthcare starts with accurate diagnosis, yet across Africa, only around 30% of health facilities have the equipment required for basic testing. This leaves millions vulnerable to undetected infectious diseases, such as HIV and tuberculosis, as well as limited or late detection of non communicable diseases such as cancer.
Climate change is exacerbating this. Conventional testing kits require continuous refrigeration, a major barrier for low-income and rural communities with unstable power. At the same time, climate-sensitive diseases are on the rise, increasing pressure on already fragile health systems and supply chains.
The innovation
Reme.D is revolutionising how disease is detected. Using patented nanotechnology and advanced preservation techniques, Reme.D manufactures medical test kits in Egypt that remain effective at high temperatures with no refrigeration needed.
By removing the need for refrigeration, Reme.D is breaking the cold chain barrier that often leaves rural and low-income communities excluded from access to molecular testing.
Reme.D have developed a product suite covering 30 diseases, including test kits, lab supplies, high-tech diagnostic devices, and portable units that can be taken directly into the field.
Our investment
GIF is participating in Reme.D's pre-Series A round with a $500,000 equity investment. The funding will support the Company’s working capital needs, and enable Reme.D to scale commercially in Egypt, Kenya, and new markets, expand its facilities, and secure further regulatory advancements.
Reme.D in numbers
diseases covered by diagnostic test range
patients tested since 2023
customers in Egypt alone